BPC-157 in 2026: Chemistry, Analytical Documentation and Laboratory Handling

In the landscape of peptide chemistry, a small number of synthetic sequences appear again and again in the published literature, in supplier catalogs and in laboratory inventories. BPC-157, a synthetic pentadecapeptide, is one of them. It has been examined in published in-vitro and animal research for more than three decades, and in 2026 it remains one of the most frequently catalogued research peptides. That visibility makes it a useful case study in how a laboratory should approach a research compound: by its chemistry, its documentation and its handling, rather than by claims made about it.

This overview covers what BPC-157 is chemically, how the published literature is organized, how identity and composition are verified analytically, how a Certificate of Analysis should be read, and how the lyophilized material should be received, stored and recorded in a laboratory setting.

For in-vitro laboratory research use only. Not for human consumption.

What is BPC-157? Chemical Identity

BPC-157 is a synthetic peptide composed of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (single-letter code GEPPPGKPADDAGLV). Its sequence corresponds to a partial fragment of a larger protein originally isolated from gastric juice, which is where the "BPC" designation comes from. The research material is produced entirely by chemical synthesis. Its molecular formula is C62H98N16O22 and its average molecular weight is approximately 1419.5 g/mol (CAS 137525-51-0).

Because the sequence is short, contains no cysteine, methionine or tryptophan, and carries no post-translational modifications, BPC-157 is a comparatively simple molecule to synthesize, purify and characterize. That simplicity is one reason it is often used as an example when laboratories evaluate the analytical documentation offered by a supplier.

Research Context: What Has Been Studied

The published literature on BPC-157 is large, but it is concentrated. Most papers come from a small number of research groups, and nearly all of the work consists of cell-culture experiments and rodent studies. The subsections below describe the peptide's structure and the scope of that literature in neutral terms, without drawing conclusions about outcomes.

Sequence Composition

Of the 15 residues, four are proline (positions 3, 4, 5 and 8), three are glycine, two are alanine and two are aspartic acid. The remaining positions are occupied by one residue each of glutamic acid, lysine, leucine and valine. The high proline content, including the Pro-Pro-Pro motif near the N-terminus, restricts backbone flexibility and favours extended conformations rather than a compact folded structure.

Charge and Polarity

At neutral pH the peptide carries three acidic side chains (one glutamate and two aspartates) and a C-terminal carboxylate, against one lysine side chain and the free N-terminal amine. The net charge at pH 7 is therefore approximately -2, and the theoretical isoelectric point lies in the acidic range, near pH 4. This charge profile influences its retention behaviour in reversed-phase chromatography and its ionization pattern in mass spectrometry.

Synthesis Route

Research-scale BPC-157 is produced by solid-phase peptide synthesis (SPPS), typically using Fmoc chemistry. Amino acids are coupled one at a time to a resin-bound chain, the finished peptide is cleaved from the resin, and the crude product is purified by preparative reversed-phase HPLC. The purified fractions are pooled, converted to the desired salt form (commonly acetate) and lyophilized to a dry powder.

Scope of the Published Literature

Published work on BPC-157 spans journals in pharmacology, physiology and cell biology from the early 1990s onward. Papers describe the compound in cultured cell systems and in rodent models, and several reviews summarize that body of work (Sikiric et al., 2013; Seiwerth et al., 2018). The literature is useful to laboratories mainly as context for experimental design: it documents the model systems, controls and analytical approaches other groups have used.

Why BPC-157 Remains a Frequently Catalogued Research Compound in 2026

The persistent and growing interest in BPC-157 within specialized research communities in 2026 can be attributed to several factors:

A Large Citable Literature — New papers continue to appear each year, most of them preclinical. For laboratories, a large literature means that methods sections, model descriptions and analytical approaches can be cross-referenced when planning new in-vitro work.

A Well-Defined, Unmodified Sequence — The peptide has a fixed 15-residue sequence with no modifications, disulfide bonds or unusual residues, which makes identity confirmation straightforward and keeps inter-supplier comparisons simple.

Analytical Tractability — BPC-157 elutes as a single well-resolved peak under standard reversed-phase conditions and produces a clear multiply-charged ion series by electrospray mass spectrometry, so both purity assessment and identity confirmation are routine.

A Clear Regulatory Status — BPC-157 is not approved by the FDA or any comparable agency for human use. It is sold for in-vitro laboratory research only, which gives laboratories an unambiguous framework for purchasing and recordkeeping.

What to Look For in a BPC-157 Source

Reproducible laboratory work starts with documented identity and composition. When sourcing BPC-157 for in-vitro research, laboratories typically look for:

• A published Certificate of Analysis that reports HPLC purity and identity confirmation (LC-MS or FTIR) for the product
• Clear salt-form information (acetate or other counter-ion) so molar calculations can be made correctly
• Stated storage conditions for the lyophilized powder
• Legible, consistent labeling that matches the documentation
• Research-use-only positioning with no human-use language in product copy or packaging

BPC-157 from Excalibur Peptides

Excalibur Peptides is a U.S.-based research peptide supplier. Our BPC-157 is supplied as a lyophilized powder in sealed vials for in-vitro laboratory research. It was third-party tested by Freedom Diagnostics Testing (search code Exca2610050652), with purity by HPLC and identity by LC-MS, and the Certificate of Analysis can be reviewed on the product page and in our COA database. For a related overview of another frequently catalogued sequence, see our TB-500 (Thymosin Beta-4) research overview.

View BPC-157 →

References: Sikiric P. et al. (2013). J Physiol Pharmacol. 64(2):177-187 · Sikiric P. et al. (2009). Eur J Pharmacol. 606(1-3):200-207 · Smart N. et al. (2011). Circ Res. 109(6):661-671

Structural Chemistry of BPC-157

For laboratories, the most practical way to understand a research peptide is through its structure. Sequence, charge, hydrophobicity and the presence or absence of chemically sensitive residues determine how the compound behaves during synthesis, purification, analysis and storage. This section examines those properties for BPC-157 in more detail.

Backbone Conformation and the Polyproline Motif

The Pro-Pro-Pro stretch at positions 3 to 5, together with a further proline at position 8, gives the N-terminal half of BPC-157 a strong tendency toward a polyproline II (PPII) conformation. PPII is an extended, left-handed helical arrangement that does not rely on internal hydrogen bonds, and it is common in short proline-rich peptides in aqueous solution. Circular dichroism spectroscopy is the usual technique for assessing this kind of structure, and short peptides such as BPC-157 generally show spectra consistent with a mixture of PPII and disordered conformations rather than a single stable fold.

The practical consequence is that BPC-157 behaves as a flexible, largely unstructured molecule. It has no tertiary structure to lose, so the concerns about unfolding that apply to proteins do not apply in the same way. However, like all peptides it remains subject to chemical degradation, aggregation at high concentration and adsorption to surfaces, which are the handling topics addressed later in this article.

Chemically Sensitive Residues

A useful step when evaluating any peptide is to list the residues that are most prone to chemical change:

• Methionine and cysteine are the residues most susceptible to oxidation. BPC-157 contains neither.
• Tryptophan is sensitive to light and oxidation. BPC-157 contains none.
• Asparagine and glutamine can undergo deamidation. BPC-157 contains neither.
• Aspartic acid can form a cyclic succinimide intermediate that rearranges to isoaspartate. BPC-157 contains two adjacent aspartates (positions 10 and 11), which is the main chemical liability in the sequence.

Aspartimide formation is also a well-known side reaction during Fmoc solid-phase synthesis of aspartate-containing sequences. Manufacturers control it through choice of protecting groups and coupling conditions, and any resulting by-products are removed during preparative HPLC. Isoaspartate variants have the same mass as the parent peptide, so they cannot be distinguished by mass spectrometry alone; they are detected as closely eluting peaks in a well-optimized HPLC method.

Absence of Aromatic Residues and Its Analytical Consequences

BPC-157 contains no phenylalanine, tyrosine or tryptophan. Consequently, it has negligible absorbance at 280 nm, the wavelength commonly used to quantify proteins. Analytical HPLC of BPC-157 therefore relies on detection at 210 to 220 nm, where the peptide bond itself absorbs. This matters when reviewing a chromatogram: the detection wavelength should be stated, and it should fall in the low-UV range. It also means that simple UV spectrophotometry at 280 nm is not a suitable method for estimating BPC-157 concentration in solution.

Hydrophobicity and Chromatographic Behaviour

With leucine and valine at the C-terminus and several prolines and alanines along the chain, BPC-157 has moderate hydrophobicity balanced by its acidic residues. On a C18 reversed-phase column with a water/acetonitrile gradient containing 0.1% trifluoroacetic acid, it elutes in the lower-to-middle portion of a typical gradient. Truncated sequences produced during synthesis (for example, peptides missing one proline) usually elute slightly earlier or later than the full-length product and appear as small neighbouring peaks.

Mass Spectrometric Signature

The monoisotopic mass of BPC-157 is approximately 1418.70 Da and the average mass approximately 1419.5 Da. Under electrospray ionization it is typically observed as protonated ions, with the doubly charged [M+2H]2+ ion near m/z 710.8 often being the most abundant, alongside the singly charged [M+H]+ ion near m/z 1420.5. Sodium and potassium adducts may appear at +22 and +38 Da relative to the protonated species. These values provide a simple identity check when reviewing mass spectrometry data.

Contextualizing BPC-157 in the Published Preclinical Literature

BPC-157 has been examined in published in-vitro and animal research since the early 1990s. It is not approved for human use in the United States or elsewhere, and no regulatory agency has approved a medicinal product containing it. For laboratories, the literature is most usefully treated as a record of methods and model systems rather than as a source of conclusions. The sections below describe how that literature is organized and how to read it critically.

Who Publishes on BPC-157

A large share of BPC-157 papers originates from a single research group at the University of Zagreb, led by Predrag Sikiric, which has published on the compound continuously since 1993. Additional in-vitro work has come from groups in Taiwan (Chang, Pang and colleagues) and from a smaller number of independent laboratories elsewhere. Concentration of a literature in one group is not unusual for a niche compound, but it is an important context point: independent replication by unrelated laboratories is one of the main ways a scientific finding gains weight.

Types of Studies

The literature can be grouped by experimental system:

• Cell-culture studies in which cultured cells are exposed to BPC-157 in defined media and a range of molecular and cellular readouts are measured (Chang et al., 2011; Wang et al., 2021).
• Rodent studies in which the compound is examined in rats or mice under controlled laboratory conditions (Sikiric et al., 1993; Pevec et al., 2010).
• Other animal studies, a much smaller group that includes work in rabbits (Sebecic et al., 1999).
• Narrative reviews, mostly written by the originating group, which summarize the preceding categories (Sikiric et al., 2013; Sikiric et al., 2017; Seiwerth et al., 2018).

No controlled studies establishing any human use have been published, and nothing in the preclinical record should be read as indicating one.

Reading the Literature Critically

When a laboratory reviews BPC-157 papers to inform its own in-vitro design, several questions are worth asking of each study:

• What material was used? Many papers describe the peptide's source only briefly. Look for the supplier, salt form, stated purity method and whether identity was confirmed, for example by LC-MS or FTIR.
• How was the material prepared and stored? Solvent, concentration, storage temperature and the time between preparation and use all affect reproducibility.
• What controls were included? Vehicle controls, scrambled-sequence controls and positive controls help separate specific effects from artifacts.
• What was the sample size, and was the analysis pre-specified? Small groups and post-hoc analyses reduce the strength of any single paper.
• Has the observation been independently repeated? A finding reported by several unrelated laboratories is more robust than one reported repeatedly by a single group.

Why Independent Documentation Matters

The same principles apply to a laboratory's own work. A methods section that states the supplier, the Certificate of Analysis reference, the salt form, the storage conditions and the preparation date allows other groups to reproduce the work with comparable material. For a compound whose literature is concentrated in a few groups, careful documentation by new laboratories adds real value to the field.

Analytical Documentation: Reading a BPC-157 Certificate of Analysis

A Certificate of Analysis (COA) is the key document accompanying a research peptide. It records the analytical tests performed on the material analyzed, a sample of the product, and the results used to establish its identity and composition. Learning to read a COA is as important to a laboratory as any other routine technique. The sections below describe what a typical COA for BPC-157 contains.

Section 1: Product Identification

• Product Name: Should clearly state "BPC-157".
• CAS Number: 137525-51-0. This unique chemical identifier allows cross-referencing in chemical databases.
• Molecular Formula: C62H98N16O22. This specifies the exact number of carbon, hydrogen, nitrogen and oxygen atoms in the molecule.
• Molecular Weight: approximately 1419.5 g/mol. This theoretical value is the reference point for identity confirmation by mass spectrometry.
• Sample or Reference Number: An identifier that links the document to the specific material that was analyzed, useful for recordkeeping and for any query to the supplier.

Section 2: Analytical Test Data

This is the core of the COA, presenting data from laboratory tests.

• Appearance: Typically "white lyophilized powder" or similar. Discoloration, a collapsed or sticky cake, or visible moisture can indicate degradation or improper storage.
• Purity (by HPLC): Reported as the percentage of total UV-absorbing peak area attributable to the main BPC-157 peak. The COA should state the detection wavelength, and ideally the column and gradient used, so the figure can be interpreted. Purity describes how much of the detected material is the target sequence rather than synthesis-related by-products such as deletion or truncated sequences.
• Identity (by LC-MS or FTIR): For LC-MS, the observed mass, or the observed mass-to-charge values of the main ions, compared with the theoretical molecular weight; for FTIR, a match between the sample's infrared spectrum and the reference spectrum. Either result confirms that the main HPLC peak is BPC-157 rather than an unrelated compound with a similar retention time. The BPC-157 COA published by Excalibur Peptides, issued by Freedom Diagnostics Testing, reports identity by LC-MS.
• Net Peptide Content: A distinct measurement from purity. It is the fraction of the total powder mass that is peptide, with the remainder made up of counter-ions (such as acetate or trifluoroacetate) and residual water. Net peptide content is usually determined by amino acid analysis or elemental nitrogen analysis, and it is needed for accurate molar quantification in analytical work. Confusing purity with net peptide content is a common source of calculation error.
• Water Content (by Karl Fischer): Residual moisture in the lyophilized cake. Low values indicate effective freeze-drying and appropriate packaging.
• Counter-ion Content: The identity and amount of the counter-ion, most commonly acetate or trifluoroacetate (TFA). TFA is carried over from reversed-phase purification; acetate is obtained by a salt-exchange step. Because residual TFA can interfere with some cell-based assays, laboratories often note the salt form in their records.

Section 3: Conclusion and Sign-off

• Storage Conditions: The recommended storage temperature for the lyophilized powder, typically -20°C.
• Conclusion: A statement such as "The product conforms with the specification."
• Reviewer Signature and Date: The signature of the analyst or reviewer who approved the data, which adds accountability to the document.

A clear, complete COA allows a laboratory to confirm what it has received and to document that material properly in its own records.

The Science of Verification: Third-Party Laboratory Testing Methodologies

The figures on a Certificate of Analysis are only as meaningful as the analytical methods used to generate them. For research peptides, identity and composition are established with a small set of complementary techniques, each answering a different question. Understanding how these methods work makes it easier to judge whether a COA is complete.

High-Performance Liquid Chromatography (HPLC) for Purity Assessment

HPLC is the standard technique for assessing the chromatographic purity of a peptide sample. The principle behind it is separation science.

1. The System: An HPLC system consists of a solvent reservoir, a high-pressure pump, an injector, a column, and a detector. The column is the heart of the system, packed with a solid material (the stationary phase), typically silica with C18 (18-carbon chains) bonded to it for reversed-phase HPLC, which is standard for peptides.
2. The Process: A small, precisely measured amount of the dissolved BPC-157 sample is injected into a stream of a liquid solvent (the mobile phase) being pushed through the column by the pump at high pressure.
3. Separation: As the mixture travels through the column, different molecules interact with the stationary phase to varying degrees. BPC-157, being a relatively hydrophobic molecule, will "stick" to the hydrophobic C18 stationary phase. Synthesis-related impurities, which may be more or less hydrophobic, will travel at different speeds. The composition of the mobile phase is gradually changed (a "gradient") to become more non-polar, which systematically "washes" the molecules off the column, starting with the least retained and ending with the most retained.
4. Detection: As each component exits the column, it passes through a detector, typically a UV-Vis detector set to a wavelength where peptide bonds absorb light (around 214-220 nm). The detector measures the absorbance, which is proportional to the concentration of the substance.
5. The Chromatogram: The output is a chromatogram, a graph of absorbance versus time. Each separated component appears as a peak. The large, main peak represents BPC-157. Any smaller peaks represent impurities. The purity is calculated by dividing the area of the main peak by the total area of all peaks in the chromatogram. The resulting percentage describes the proportion of UV-absorbing material in the sample that is the target peptide under the stated method conditions.

Mass Spectrometry (MS) for Identity Confirmation

While HPLC confirms purity, it doesn't definitively prove identity. It's possible for an impurity to have a similar retention time to the target compound. Mass Spectrometry solves this by measuring the molecular weight with extreme precision.

1. Ionization: The sample, often collected directly from the HPLC outflow (a technique called LC-MS), is introduced into the mass spectrometer's ion source. For peptides, Electrospray Ionization (ESI) is commonly used. ESI creates a fine spray of charged droplets, and as the solvent evaporates, it leaves behind charged peptide molecules (ions) in the gas phase.
2. Mass Analysis: These ions are then guided into a mass analyzer (e.g., a quadrupole or time-of-flight analyzer). The analyzer separates the ions based on their mass-to-charge ratio (m/z).
3. Detection: A detector counts the number of ions at each m/z value. The output is a mass spectrum, a graph of ion intensity versus m/z.
4. Verification: For BPC-157, which has a theoretical molecular weight of 1419.5 g/mol, the spectrum should show a prominent peak corresponding to this mass. Because ESI often adds one or more protons (H⁺, mass ~1.008), the instrument will detect ions like [M+H]⁺ at m/z ≈ 1420.5, [M+2H]²⁺ at m/z ≈ 710.75, or [M+3H]³⁺ at m/z ≈ 474.1. Finding this characteristic pattern of peaks provides unambiguous confirmation that the compound is indeed BPC-157.

FTIR Spectroscopy as an Identity Method

Fourier-transform infrared spectroscopy (FTIR) is a second, widely used identity method. The instrument records how the sample absorbs infrared light across a range of wavenumbers, producing a spectrum shaped by the peptide backbone (the amide I and amide II bands) and by side-chain functional groups. Identity is confirmed when the sample spectrum matches the reference spectrum for the compound. FTIR does not report a molecular mass, but paired with HPLC it confirms that the material is the stated compound. The BPC-157 Certificate of Analysis published by Excalibur Peptides was issued by Freedom Diagnostics Testing and reports purity by HPLC and identity by LC-MS.

Limulus Amebocyte Lysate (LAL) for Endotoxin Testing

Endotoxins are components of the outer membrane of Gram-negative bacteria. Even at very low levels they can activate innate immune signaling in cultured cells, which can confound cell-based experiments. For that reason, endotoxin levels are often measured for peptides intended for biological assays.

The LAL test is an incredibly sensitive assay that uses amoebocyte lysate derived from the blood of the Atlantic horseshoe crab (Limulus polyphemus). The lysate contains proteins that trigger a coagulation cascade in the presence of minute amounts of endotoxin.

• Gel-Clot Method: The simplest form involves mixing the sample with the LAL reagent in a test tube. If endotoxin levels are above a certain threshold, the solution will form a solid gel.
• Chromogenic Method: A more quantitative method involves a modified LAL reagent containing a chromogenic substrate. In the presence of endotoxin, the cascade cleaves the substrate, releasing a colored molecule (a chromophore). The amount of color produced, measured with a spectrophotometer, is directly proportional to the endotoxin concentration. Values are reported in Endotoxin Units per milligram (EU/mg). Specifications for peptides intended for cell-based work are typically set at a low level and stated on the COA when the test has been performed.

Karl Fischer Titration for Water Content

Water can promote peptide degradation through hydrolysis, so minimizing its presence in the lyophilized powder is vital for long-term stability. The Karl Fischer titration is the standard method for quantifying water content. It's a chemical analysis based on a reaction involving iodine, sulfur dioxide, a base, and an alcohol. Water reacts with the reagents in a 1:1 molar ratio. The endpoint of the titration is detected potentiometrically when all the water has been consumed. It is far more specific and accurate for water than a simple "loss on drying" method, which would also measure residual solvents.

From Synthesis to Laboratory: Sourcing, Storage and Shipping

The journey of a research peptide from the synthesis reactor to a laboratory freezer affects its integrity and the validity of any experiment that uses it. Good practice extends beyond synthesis and analysis into how the material is dried, packaged, stored before dispatch and shipped. For lyophilized material, the longest and most important stage is usually storage: how recently the batch was made and how cold it has been kept before it ships.

The Importance of Lyophilization

BPC-157, like most peptides, is synthesized in a solution. In this state, it is vulnerable to degradation, primarily through hydrolysis (cleavage of peptide bonds by water) and oxidation. To ensure long-term stability for storage and shipping, the peptide must be converted into a solid state. This is achieved through lyophilization, or freeze-drying.

1. Freezing: The purified peptide solution is placed in vials and frozen solid, typically at a very low temperature (e.g., -40°C or below). This locks the water molecules in place as ice crystals.
2. Primary Drying (Sublimation): The vials are then placed under a deep vacuum. The temperature is raised slightly, but the pressure remains very low. This causes the frozen water to change directly from a solid (ice) to a gas (water vapor) without passing through the liquid phase—a process called sublimation. This gentle removal of water prevents the collapse of the peptide's delicate structure.
3. Secondary Drying (Desorption): After the bulk of the ice is removed, the temperature is raised further to remove any remaining water molecules that are bound to the peptide itself.
4. Backfilling and Sealing: Once dried, the vials are often backfilled with an inert gas, such as nitrogen or argon, to displace oxygen and further prevent oxidation. They are then immediately sealed with a rubber stopper and crimp cap to create an airtight environment. The product is a light, airy "cake" of lyophilized BPC-157 powder, which degrades far more slowly than the peptide in solution when stored properly at low temperatures.

Storage Before Dispatch and Shipping

Heat and time are the main drivers of slow peptide degradation. How recently a batch was made and how cold it was kept before dispatch both affect how much degradation it carries on arrival.

• Supplier Storage: Suppliers commonly store bulk lyophilized peptides in industrial-grade, temperature-monitored freezers, typically at -20°C or -80°C. Access is controlled, and temperature logs are maintained to ensure there have been no deviations.
• Shipping: Excalibur makes each product in fresh batches, freezes it and keeps it at -10 °F until the day it ships; orders go out from the U.S. with tracking.
• Researcher's Responsibility: Cold storage resumes in the receiving laboratory. It is important that researchers unpack and transfer incoming peptides to a suitable freezer (ideally -20°C) promptly upon arrival. Leaving a package on a loading dock or lab bench for days rather than hours adds avoidable time at room temperature to the material's history. Shipment tracking information helps ensure that the delivery can be anticipated and handled promptly.

Researchers can reasonably ask any supplier how recently the material was made, how it is stored before dispatch and what storage conditions are recommended on arrival. Clear answers to those questions are part of the documentation that supports reproducible work.

Laboratory Receipt, Storage and Recordkeeping for Lyophilized BPC-157

Once a vial of lyophilized BPC-157 arrives in the laboratory, its integrity depends on how it is received, stored and tracked. The practices below apply to the dry, lyophilized material and to the documentation that accompanies it. They are general laboratory practices for research chemicals and do not describe any form of use outside the laboratory.

Receiving a Shipment

• Inspect the outer packaging for damage, crushing or signs of exposure to moisture.
• Check each vial for an intact seal and crimp cap, legible labeling and a dry, uniform powder or cake.
• Match the label to the documentation. The product name and any reference number on the vial should correspond to the Certificate of Analysis on file.
• Record the receipt in the laboratory inventory: date received, quantity, storage location and the COA reference.
• Transfer promptly to storage. Packages should not be left on a bench or loading dock for extended periods.

Storage Conditions for the Lyophilized Powder

Lyophilized peptides are considerably more stable than peptides in solution, but they are not indifferent to their environment. The main factors are temperature, moisture, light and oxygen.

• Temperature: Keep the sealed vial at the storage temperature listed on the product page (−20 °C).
• Moisture: Lyophilized peptides are hygroscopic. Keeping vials sealed and, where practical, storing them inside a secondary container with desiccant reduces moisture uptake.
• Light: Although BPC-157 lacks the most light-sensitive residues, storing vials in their outer carton or in an opaque box is a simple precaution that applies to all research peptides.
• Temperature stability of the freezer: Manual-defrost freezers are preferred over frost-free units, which periodically warm to prevent ice build-up. A temperature log or monitoring device documents that storage conditions were maintained.

Opening and Weighing the Dry Powder

When a vial must be opened, for example to weigh material for an analytical standard, a few precautions protect the remaining contents:

• Equilibrate to room temperature first. Allow the sealed vial to warm for 15 to 20 minutes before opening. Opening a cold vial draws in humid air, and condensation forms on the powder.
• Work quickly in low humidity. Minimize the time the vial is open, and reseal it promptly.
• Use a calibrated analytical balance. Small peptide quantities require a microbalance or semi-microbalance, and static control (an ionizing bar or antistatic weighing boats) improves accuracy with light, fluffy powders.
• Account for net peptide content. The mass weighed is total powder, not pure peptide. The net peptide content on the COA is used to convert between the two in analytical calculations.

Personal Protective Equipment and Hazard Information

Standard laboratory PPE (gloves, lab coat and eye protection) applies when handling any research peptide. Fine lyophilized powders can become airborne when a vial is opened, so weighing in a draft-shielded balance enclosure is good practice. Hazard, handling and disposal information is provided in Safety Data Sheets, available from our Safety Data Sheets page.

Inventory, Traceability and Disposal

A simple inventory record for each vial should include the product name, supplier, COA reference, date received, storage location, each date the vial was opened and the remaining quantity. This record supports traceability if a question about the material ever arises and allows methods sections to cite the material accurately. Expired, unused or unneeded material should be disposed of through the institution's chemical waste procedures, in accordance with the Safety Data Sheet and local regulations.

Comparative Chemistry: BPC-157 and Other Frequently Catalogued Peptides

BPC-157 is often listed alongside other research peptides in supplier catalogs. Comparing their basic chemistry is useful for laboratories that maintain several of these compounds, because sequence length, molecular weight and composition drive differences in analysis and handling.

This comparison shows how differently three frequently catalogued peptides behave as chemicals. BPC-157 is a short, unmodified sequence with one main chemical liability; thymosin beta-4 is a much larger acetylated peptide with several oxidation- and deamidation-prone residues; and GHK-Cu is a metal complex whose analysis must account for both the peptide and the copper. Each requires its own analytical approach and storage discipline, and each should be documented separately in laboratory records.

Expanded FAQ for Researchers

1. What is the difference between BPC-157 acetate and BPC-157 arginate? The two forms contain the same 15-residue peptide sequence and differ only in the counter-ion paired with the peptide's charged groups. The acetate salt is the form most commonly supplied for research. The arginate salt uses arginine as the counter-ion and is described by some suppliers as having different solubility and solution-stability characteristics. Because the counter-ion changes the total mass of the powder, the salt form must be recorded and taken into account in any molar calculation.

2. Why does a COA report both an HPLC result and an identity result? The two techniques answer different questions. HPLC separates the components of the sample and shows what proportion of the UV-absorbing material is the main peak. An identity test, either mass spectrometry (LC-MS), which measures the molecular mass of that main peak, or FTIR, which matches the sample's infrared spectrum to a reference, confirms that it corresponds to BPC-157. A purity figure without identity confirmation cannot rule out that the main peak is a different compound, and an identity confirmation without chromatographic data cannot show how much of the sample is the target sequence. Together they establish both identity and composition.

3. What does "pentadecapeptide" mean? A pentadecapeptide is a peptide made up of fifteen amino acid residues joined by peptide bonds. BPC-157 is often described this way in the literature, for example as "pentadecapeptide BPC 157" in paper titles. The term is purely structural: it describes the length of the chain and nothing else about the compound. Similar terms include tripeptide (three residues, such as GHK) and hexapeptide (six residues).

4. Why should a vial of lyophilized peptide warm to room temperature before it is opened? A vial taken straight from a freezer is colder than the surrounding air. If it is opened immediately, humid air enters and moisture condenses on the cold powder. Lyophilized peptides are hygroscopic, and absorbed water accelerates chemical degradation over time. Leaving the sealed vial at room temperature for 15 to 20 minutes before opening prevents condensation and helps preserve the remaining material.

5. How does net peptide content on a COA affect laboratory calculations? Net peptide content is the fraction of the powder's mass that is actually peptide. The remainder consists of counter-ions and residual water. If a vial contains a given mass of powder, only that fraction is BPC-157. Any calculation of molar quantity, for example when preparing an analytical reference standard, should be based on the peptide mass rather than the total powder mass. Ignoring net peptide content is a common source of error in quantitative analytical work.

6. Is BPC-157 the same as the naturally occurring gastric protein? No. BPC-157 is a 15-amino acid sequence corresponding to a fragment of a larger protein described in gastric juice. The research compound is produced entirely by chemical synthesis and consists only of that 15-residue sequence. Its chemical and physical properties are those of a short synthetic peptide and should not be assumed to match those of the larger native protein.

7. Why is BPC-157 lyophilized instead of being sold as a liquid? Peptides in solution are susceptible to degradation over time through hydrolysis. Lyophilization (freeze-drying) removes water, converting the peptide into a solid powder, which slows degradation compared with a solution. Kept sealed, cold and dry, the lyophilized powder changes far more slowly than the same peptide in solution.

8. Does BPC-157 contain residues that are prone to oxidation? No. The residues most susceptible to oxidation are methionine, cysteine and tryptophan, and BPC-157 contains none of them. Its main chemical liability is the adjacent pair of aspartic acid residues at positions 10 and 11, which can slowly form isoaspartate variants through a cyclic succinimide intermediate. This is one reason dry, cold storage of the lyophilized powder is recommended.

9. What should a laboratory check when a BPC-157 shipment arrives? Check that the outer packaging is undamaged, that each vial is sealed and legibly labeled, and that the powder appears dry and uniform. Confirm that the product name and any reference number match the Certificate of Analysis on file. Record the date of receipt, the quantity and the storage location in the laboratory inventory, then transfer the vials to the recommended storage temperature without delay.

10. What are counter-ions, and why do they matter? During the final purification step of peptide synthesis (usually RP-HPLC), acids like trifluoroacetic acid (TFA) or acetic acid are used. The final peptide is an ionic salt with the positively charged amino groups of the peptide associated with the negatively charged acid molecules (counter-ions). While necessary for purification and stability, high concentrations of some counter-ions, particularly TFA, can have their own biological effects (e.g., cytotoxicity in sensitive assays). A COA should specify the counter-ion and its concentration, allowing researchers to choose the most appropriate salt form (e.g., Acetate vs. TFA) for their specific experimental model.

Glossary of Technical Terminology

• Amino Acid: The fundamental molecular building blocks of proteins and peptides.
• Aspartimide: A cyclic succinimide intermediate formed from aspartic acid residues, which can rearrange to isoaspartate. A known side reaction in peptide synthesis and storage.
• Assay: A laboratory procedure for measuring the activity, concentration or presence of a substance.
• Certificate of Analysis (COA): A document that records the analytical tests performed on a product and confirms that it meets its stated specifications.
• Counter-ion: An ion that accompanies an ionic species to maintain electrical neutrality. In peptides, this is often acetate or trifluoroacetate left over from purification.
• Electrospray Ionization (ESI): A soft ionization technique used in mass spectrometry that produces intact, often multiply charged ions from molecules in solution.
• Fmoc SPPS: Solid-phase peptide synthesis using the 9-fluorenylmethoxycarbonyl protecting group, the most common method for producing research peptides.
• High-Performance Liquid Chromatography (HPLC): An analytical technique used to separate, identify and quantify each component in a mixture. It is the standard method for determining peptide chromatographic purity.
• In-Vitro: (Latin for "in glass") Research conducted with cells or biological molecules outside a living organism, such as in a test tube or culture dish.
• Isoelectric Point (pI): The pH at which a molecule carries no net electrical charge.
• Lyophilization: A low-temperature dehydration process that involves freezing the product, lowering pressure, then removing the ice by sublimation. Also known as freeze-drying.
• Mass Spectrometry (MS): An analytical technique that measures the mass-to-charge ratio of ions. It is used to confirm the molecular weight and thus the identity of a peptide.
• Net Peptide Content: The proportion of a lyophilized powder's total mass that is peptide, as opposed to counter-ions and water.
• Polyproline II (PPII) Helix: An extended, left-handed helical conformation common in proline-rich peptide sequences.

Expanded References

Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. J Appl Physiol. 2011;110(3):774-780.

Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, et al. Med Sci Monit. 2010;16(3):BR81-BR94.

Sebecic B, Nikolic V, Sikiric P, Seiwerth S, Sosa T, Patrlj L, et al. Bone. 1999;24(3):195-202.

Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Curr Neuropharmacol. 2017;15(6):857-865.

Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. Eur J Pharmacol. 1993;246(3):321-326.

Sikiric P, et al. J Physiol Pharmacol. 2013;64(2):177-187.

Seiwerth S, et al. Curr Pharm Des. 2018;24(18):1972-1989.

Vuksic T, Zoricic I, Brcic L, Sever M, Klicek R, Radic B, et al. J Physiol Pharmacol. 2007;58(Suppl 3):191-203.

Wang DW, Hsu YH, Lin YM, Chang CH, Pang JHS. J Orthop Surg Res. 2021;16(1):1-8.

Disclaimer: The products mentioned are intended for in-vitro laboratory research and development purposes only. They are not for any form of human or veterinary use. The information presented here is for educational and informational purposes and is based on preclinical research findings. It does not constitute medical advice or an endorsement of any kind. All research involving these compounds must be conducted by qualified professionals in a controlled laboratory setting in accordance with all applicable laws and regulations. Any discussion of mechanisms or applications refers strictly to observations in non-human, preclinical research models. For any support or quality control questions related to our research compounds, please contact us at info@excaliburpeptides.com.